R Bottlender
Overview
Explore the profile of R Bottlender including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
651
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bechdolf A, Wagner M, Ruhrmann S, Harrigan S, Putzfeld V, Pukrop R, et al.
Br J Psychiatry
. 2011 Nov;
200(1):22-9.
PMID: 22075649
Background: Young people with self-experienced cognitive thought and perception deficits (basic symptoms) may present with an early initial prodromal state (EIPS) of psychosis in which most of the disability and...
2.
Moller H, Jager M, Riedel M, Obermeier M, Strauss A, Bottlender R
Eur Psychiatry
. 2010 Jul;
26(4):231-43.
PMID: 20621452
Objective: In the context of the development of DSM-V and ICD-11 it appears to be useful to get further data on the validity of the diagnostic differentiation between schizophrenic and...
3.
Jager M, Riedel M, Obermeier M, Schennach-Wolff R, Seemuller F, Messer T, et al.
Schizophr Res
. 2010 Feb;
118(1-3):183-8.
PMID: 20181461
Objective: To describe the course of positive and negative symptoms during inpatient treatment and examine remission and response rates under routine clinical care conditions. Methods: Two hundred and eighty inpatients...
4.
Frodl T, Koutsouleris N, Bottlender R, Born C, Jager M, Morgenthaler M, et al.
Mol Psychiatry
. 2008 Nov;
13(12):1093-101.
PMID: 19008895
The serotonergic system is involved in the pathophysiology of major depression as well as in the early central nervous system development and adult neuroplasticity. The aim of the study was...
5.
Jager M, Messer T, Laux G, Pfeiffer H, Naber D, Schmidt L, et al.
Pharmacopsychiatry
. 2008 Sep;
41(5):190-5.
PMID: 18763221
Introduction: Standardized consensus criteria for remission in schizophrenia were recently proposed. As yet, the validity of these criteria and their comparability with previously used outcome measures are unclear. Methods: The...
6.
Meisenzahl E, Koutsouleris N, Bottlender R, Scheuerecker J, Jager M, Teipel S, et al.
Schizophr Res
. 2008 Aug;
104(1-3):44-60.
PMID: 18703313
Structural alterations in schizophrenia have mainly been regarded as the result of neurodevelopmental processes. However, it remains unresolved whether the pattern of morphological brain changes differs between different stages of...
7.
Structural brain alterations in subjects at high-risk of psychosis: a voxel-based morphometric study
Meisenzahl E, Koutsouleris N, Gaser C, Bottlender R, Schmitt G, McGuire P, et al.
Schizophr Res
. 2008 Apr;
102(1-3):150-62.
PMID: 18439804
Forty Untreated high-risk (HR) individuals for psychosis and 75 healthy control subjects (HC) matched for age, gender, handedness and educational level were investigated by structural MRI. HR subjects were recruited...
8.
Moller H, Bottlender R
Acta Psychiatr Scand Suppl
. 2006 Feb;
(429):64-8.
PMID: 16445485
Objective: The study aimed to evaluate the outcome from in-patient treatment in major depressive disorders (MDD) and its impact on the patients' 1 year outcome under the present routine care...
9.
Schmitt G, Frodl T, Dresel S, Fougere C, Bottlender R, Koutsouleris N, et al.
Eur Arch Psychiatry Clin Neurosci
. 2005 Nov;
256(2):115-21.
PMID: 16284713
Objective: Supposing a "hyperdopaminergic State" associated at least with acute psychotic illness phases in schizophrenia, a direct relationship between striatal dopamine metabolism and the core psychopathological symptoms rarely can be...
10.
Padberg F, Moller H, Bottlender R, Hampel H
MMW Fortschr Med
. 2005 Jun;
147 Spec No 2:71-4, 76-7.
PMID: 15968877
The most frequently diagnosed dementia diseases include Alzheimer disease (AD), vascular dementia (VD) and dementia with Lewy bodies. Cholinesterase (ChE) inhibitors and the NMDA receptor antagonist memantine are currently recommended...